Namilumab or infliximab compared to standard of care in hospitalised patients with COVID-19 (CATALYST): a phase 2 randomised adaptive trial (2021)

First Author: Fisher B

Attributed to: CATALYST a randomised early phase adaptive trial for new drugs for SARS-CoV-2+ patients funded by COVID

Abstract

No abstract provided

Bibliographic Information

Digital Object Identifier: http://dx.doi.org/10.1101/2021.06.02.21258204

Publication URI: http://dx.doi.org/10.1101/2021.06.02.21258204

Type: Preprint